Mátyás Keltai

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

John W. Eikelboom, Stuart J. Connolly, Jackie Bosch et al. · New England Journal of Medicine · 2017 · 2.3K citations · Full text

Initial Invasive or Conservative Strategy for Stable Coronary Disease

David J. Maron, Judith S. Hochman, Harmony R. Reynolds et al. · New England Journal of Medicine · 2020 · 2.3K citations

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

Johannes F.E. Mann, Roland E. Schmieder, Matthew McQueen et al. · The Lancet · 2008 · 1.6K citations

Hypertension, Urology, Renal Disease +12

A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease

Carl J. Pepine, Eileen Handberg, Rhonda M. Cooper‐DeHoff et al. · JAMA · 2003 · 1.3K citations